To improve the actions available to eligible product developers in the event of delays in receiving covered product for purposes of generic drug or biosimilar biological product development.
Sponsors
Legislative Progress
IntroducedMs. Hassan (for herself and Mr. Braun) introduced the following …
Ms. Hassan (for herself and Mr. Braun) introduced the following …
Ms. Hassan (for herself and Mr. Braun) introduced the following …
Ms. Hassan (for herself and Mr. Braun) introduced the following …
Ms. Hassan (for herself and Mr. Braun) introduced the following …
Ms. Hassan (for herself and Mr. Braun) introduced the following …
Ms. Hassan (for herself and Mr. Braun) introduced the following …
Ms. Hassan (for herself and Mr. Braun) introduced the following …
Ms. Hassan (for herself and Mr. Braun) introduced the following …
Ms. Hassan (for herself and Mr. Braun) introduced the following …
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology